What this means
This review found mostly animal and lab studies, plus one small human case series with no standard measures. It cannot show these products work or are safe for orthopaedic use.
Plain-English summary written by an AI model from the abstract. The original is below.
- Who it was tested in
- A review of published studies, plus one small human case series, mostly animal and lab work
- Kind of research
- A study
The science
- Original title
- Investigational Peptides in Orthopaedic Practice: Evidence, Safety, and Patient Counseling for BPC-157, Thymosin Beta-4, and TB-500.
- Authors
- Tham A, Hodgkins CW, Kennedy JG
- Journal
- The Journal of the American Academy of Orthopaedic Surgeons
- Published
- Oct 27, 2026
- Study type
- Study
- PMID
- 42937313 ↗
Abstract
Peptide-based products, particularly Body Protection Compound-157 (BPC-157), and thymosin beta-4 (TB-4), and products marketed as TB-500, are increasingly promoted for musculoskeletal recovery despite limited clinical validation. This narrative review evaluated their molecular rationale, direct musculoskeletal evidence, human safety and efficacy data, product quality concerns, regulatory status, antidoping implications, and relevance to orthopaedic counseling. PubMed/MEDLINE, EMBASE, and Scopus were searched from inception through June 2026, with additional review of primary regulatory and antidoping sources. BPC-157 has the largest bod of direct musculoskeletal preclinical evidence, including predominantly small-animal studies involving tendon, ligament, muscle, inflammatory joint disease, and bone. However, human musculoskeletal evidence is limited to one small retrospective uncontrolled case series without validated outcome measures. Validated dosing, pharmacokinetic, and long-term safety data are lacking. TB-4 has broader experimental and human experience in ophthalmic, dermatologic, and cardiovascular applications, but direct musculoskeletal evidence remains limited to in vitro and rodent studies. These nonorthopaedic findings cannot establish musculoskeletal efficacy or safety. TB-500 is a distinct seven amino-acid fragment of TB-4 that is frequently conflated with full-length TB-4 despite the absence of validated biologic or clinical equivalence. Commercial products marketed also raise concerns regarding identity, purity, concentration, sterility, and manufacturing consistency. None of these agents has an FDA-approved musculoskeletal indication, validated orthopaedic treatment protocol, or controlled human orthopaedic efficacy evidence. Orthopaedic clinicians should specifically ask about peptide use, distinguish preclinical plausibility from clinical validation, address product quality and safety uncertainties, and counsel athletes regarding antidoping restrictions. Routine clinical use cannot be currently recommended.
Tham A, Hodgkins CW, Kennedy JG Investigational Peptides in Orthopaedic Practice: Evidence, Safety, and Patient Counseling for BPC-157, Thymosin Beta-4, and TB-500. The Journal of the American Academy of Orthopaedic Surgeons. 2026. doi:10.5435/JAAOS-D-26-00049. PMID: 42937313. https://pubmed.ncbi.nlm.nih.gov/42937313/
Related research
Dysregulation of circulating damage-associated molecular patterns in diabetic foot syndrome.
BACKGROUND: Diabetic foot syndrome (DFS) is characterized by chronic inflammation, thrombotic imbalance, and impaired wound healing, yet systemic molecular alterations underlying this complication remain incompletely…
Effects of Supplementation in Masters Athletes and Older Adults: A Narrative Review.
Supplementation use in athletes is common and increasing in popularity, especially for adults seeking improvements in athletic performance.
A modified form of thymosin beta 4 helped heart tissue after heart attack in animals
Researchers changed a protein so it stays in the body longer and tested it for heart attack damage. This study was done in animals, so it does not show the same effect in people.
See all research on BPC-157 peptide →